Bristol-Myers and Celgene: Shareholders may need some convincing
January 03, 2019 at 10:59 AM EST
Bristol-Myers Squibb shareholders need convincing on the $74 billion deal for Celgene, but there is a sound logic, writes Charley Grant of WSJ’s ‘Heard on the Street’
